Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2021 2
2022 9
2023 6
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

17 results

Results by year

Filters applied: . Clear all
Page 1
High Transmission Rates of Early Omicron Subvariant BA.2 in Bangkok, Thailand.
Petcharat S, Supataragul A, Hirunpatrawong P, Torvorapanit P, Klungthong C, Chinnawirotpisan P, Ninwattana S, Thippamom N, Paitoonpong L, Suwanpimolkul G, Jantarabenjakul W, Buathong R, Joonlasak K, Manasatienkij W, Rattanatumhi K, Chantasrisawad N, Chumpa N, Cotrone TS, Fernandez S, Sriswasdi S, Wacharapluesadee S, Putcharoen O. Petcharat S, et al. Among authors: chantasrisawad n. Adv Virol. 2023 Dec 6;2023:4940767. doi: 10.1155/2023/4940767. eCollection 2023. Adv Virol. 2023. PMID: 38094619 Free PMC article.
Hybrid immunity from SARS-CoV-2 infection and mRNA BNT162b2 vaccine among Thai school-aged children.
Saraban K, Suntarattiwong P, Chantasrisawad N, Boonsathorn S, Kosalaraksa P, Phongsamart W, Tangsathapornpong A, Jaruampornpan P, Srisarang S, Puthanakit T; KIDSVAX study team. Saraban K, et al. Among authors: chantasrisawad n. Vaccine X. 2023 Nov 24;15:100414. doi: 10.1016/j.jvacx.2023.100414. eCollection 2023 Dec. Vaccine X. 2023. PMID: 38090644 Free PMC article.
Immunogenicity of BNT162b2 in children 6 months to under 5 years of age with previous SARS-CoV-2 infection, in the era of Omicron predominance.
Nantanee R, Jaru-Ampornpan P, Chantasrisawad N, Himananto O, Papakhee S, Sophonphan J, Tawan M, Jupimai T, Anugulruengkitt S, Puthanakit T; Study Team. Nantanee R, et al. Among authors: chantasrisawad n. Vaccine X. 2023 Aug 5;15:100367. doi: 10.1016/j.jvacx.2023.100367. eCollection 2023 Dec. Vaccine X. 2023. PMID: 37601322 Free PMC article.
Immunogenicity and reactogenicity of fractional, heterologous primary COVID-19 vaccination schedules with BNT162b2 boosters in 5-11-year-old Thai children: A multicenter, prospective, double-blind, randomized control trial.
Wittawatmongkol O, Bunjoungmanee P, Kosalaraksa P, Laoprasopwattana K, Boonsathorn S, Chantasrisawad N, Sudjaritruk T, Niyomnaitham S, Senawong S, Srisutthisamphan K, Quan Toh Z, Rungmaitree S, Nanthapisal S, Phanthanawiboon S, Khantee P, Techasaensiri C, Hirankarn N, Pangprasertkul S, Chokephaibulkit K. Wittawatmongkol O, et al. Among authors: chantasrisawad n. Vaccine. 2023 Sep 15;41(40):5834-5840. doi: 10.1016/j.vaccine.2023.08.021. Epub 2023 Aug 14. Vaccine. 2023. PMID: 37586956 Free article. Clinical Trial.
The immunogenicity of an extended dosing interval of BNT162b2 against SARS-CoV-2 Omicron variant among healthy school-aged children, a randomized controlled trial.
Chantasrisawad N, Techasaensiri C, Kosalaraksa P, Phongsamart W, Tangsathapornpong A, Jaru-Ampornpan P, Sophonphan J, Suntarattiwong P, Puthanakit T; KIDSVAX study team. Chantasrisawad N, et al. Int J Infect Dis. 2023 May;130:52-59. doi: 10.1016/j.ijid.2023.02.017. Epub 2023 Feb 24. Int J Infect Dis. 2023. PMID: 36841501 Free PMC article. Clinical Trial.
Immunogenicity of a Fractional Dose of mRNA BNT162b2 COVID-19 Vaccine for Primary Series and Booster Vaccination among Healthy Adolescents.
Puthanakit T, Chantasrisawad N, Yoohat K, Nantanee R, Sophonphan J, Meepuksom T, Sodsai P, Phanthanawiboon S, Jantarabenjakul W, Hirankarn N, Kosalaraksa P. Puthanakit T, et al. Among authors: chantasrisawad n. Vaccines (Basel). 2022 Sep 30;10(10):1646. doi: 10.3390/vaccines10101646. Vaccines (Basel). 2022. PMID: 36298510 Free PMC article.
Immunogenicity to SARS-CoV-2 Omicron variant among school-aged children with 2-dose of inactivated SARS-CoV-2 vaccines followed by BNT162b2 booster.
Chantasrisawad N, Puthanakit T, Kornsitthikul K, Jaru-Ampornpan P, Tawan M, Matapituk P, Sophonphan J, Anugulruengkitt S, Tangsathapornpong A, Katanyutanon A; KIDSBOOST study team*. Chantasrisawad N, et al. Vaccine X. 2022 Sep 30;12:100221. doi: 10.1016/j.jvacx.2022.100221. eCollection 2022 Dec. Vaccine X. 2022. PMID: 36213592 Free PMC article.
SARS-CoV-2 Omicron variant emerged under immune selection.
Tan CW, Chia WN, Zhu F, Young BE, Chantasrisawad N, Hwa SH, Yeoh AY, Lim BL, Yap WC, Pada SKMS, Tan SY, Jantarabenjakul W, Toh LK, Chen S, Zhang J, Mah YY, Chen VC, Chen MI, Wacharapluesadee S, Sigal A, Putcharoen O, Lye DC, Wang LF. Tan CW, et al. Among authors: chantasrisawad n. Nat Microbiol. 2022 Nov;7(11):1756-1761. doi: 10.1038/s41564-022-01246-1. Epub 2022 Oct 4. Nat Microbiol. 2022. PMID: 36195753
17 results